Table 5.

Soluble factor (pg/ml) concentrations in the serum of 10 patients who completed the study (only factors that demonstrated significant changes in concentration after the 4^th dose compared with before therapy are shown)

Soluble Factor	Average before IL-2	STD error before IL-2	Average after 4 doses	STD error after 4 doses	p value before vs. after 4 doses	Bonferroni correction
IL2*	0	0	1426	394	0.00410	0.24205
MCP2	32	9	296	34	0.00001	0.00047
I309	18	4	222	25	0.00001	0.00070
IP10	146	18	2940	390	0.00003	0.00178
VegF	865	131	1411	132	0.00003	0.00191
ITAC	29	4	438	57	0.00003	0.00200
TNFR1	1641	112	6067	651	0.00004	0.00207
IFNγ	149	21	246	16	0.00004	0.00234
IL15	0	0	14	2	0.00005	0.00269
MCP1	984	227	31267	4583	0.00006	0.00367
MIP3b	142	17	33836	5140	0.00007	0.00405
Lymph	111	22	639	95	0.00010	0.00571
E-Selectin	106029	5703	377934	40503	0.00011	0.00638
TARC	248	59	8993	1517	0.00015	0.00867
SDF1b	62	21	883	142	0.00018	0.01045
MMP8	1187	455	5081	927	0.00024	0.01406
MCP3	10	1	53	8	0.00029	0.01685
MDC	586	111	1272	214	0.00031	0.01841
Eotaxin	115	22	392	67	0.00032	0.01890
TIMP2	75277	5629	108359	4266	0.00033	0.01949
Exodus2	419	71	1108	157	0.00049	0.02911
MMP13	839	221	1742	171	0.00055	0.03224
TIMP1	198383	20136	1021646	178036	0.00071	0.04194
TNFa	521	65	839	74	0.00086	0.05090
MIP1b	512	205	4072	794	0.00105	0.06189
TNFR2	3195	259	16353	3113	0.00115	0.06774
HGF	8281	2359	17298	1311	0.00251	0.14822
IL5	0	0	40	10	0.00274	0.16167
MMP9	233004	43617	657077	142793	0.00391	0.23066
IL7	2	1	6	2	0.00508	0.29968
MMP2	210099	37913	399516	50101	0.00510	0.30111
MMP10	1467	220	3247	528	0.00545	0.32168
MCP4	84	19	1663	495	0.00698	0.41181
IL10	3	1	179	54	0.00707	0.41723
MIP3a	18	4	1346	414	0.00784	0.46274
IL6	50	5	608	184	0.01139	0.67211
VCAM1	310701	30008	1278753	336280	0.01248	0.73618
MMP3	27613	6960	59390	16227	0.01433	0.84561
KGF	373	117	505	109	0.01473	0.86914
ICAM1	499363	62669	2313052	682964	0.01505	0.88787
IL6R	23556	1882	19437	1316	0.02143	1.26450
IL4	0	0	5	2	0.02359	1.39181
IL8	61	4	296	90	0.02410	1.42202
IL18	67	11	167	43	0.03041	1.79442
IL16	13	6	104	43	0.04344	2.56278
MIP1a	2952	143	3160	156	0.05446	3.21343

Soluble Factors (pg/ml) present in the serum of patients undergoing high dose IL-2 immunotherapy were averaged before and after 4 doses of IL-2. A paired 2-tailed student t test was used to assess significance with an arbitrary cutoff of p = 0.05. Bonferroni's correction was applied to the data set by correcting for a total of 59 soluble factors (IL-2 was not factored in); IL-2 levels were included as internal control (*) since these values reflect in part administered human recombinant IL-2.